Compare EOG Resources Inc (EOG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? EOG Resources Inc trades at $155 (market cap $80.34B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: EOG Resources Inc is far larger — about 10.7× Spyre Therapeutics Inc. Common Stock's market cap, and EOG Resources Inc pays a 2.66% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EOG | SYRE | |
|---|---|---|
Market Cap | $80.34B | $7.52B |
Volume | 2,309,813 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $154.19 | $108.92 |
52-Week Low | $101.78 | $22.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $83.69B | $6.52B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $153.17, up 1.77% with strong technical momentum and bullish moving averages. The company maintains robust profitability with 25.81% net margins and consistent earnings beats, though revenue declined to $22.58B in 2025. Analyst consensus remains strongly positive with 59% buy ratings and a $163.50 price target, while recent CFO transition and dividend payments highlight stable corporate governance.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 6.02) and strong cash generation. Key risks include oil price volatility and capital expenditure intensity, but disciplined capital allocation and projected 2026 revenue growth to $26.6B support upside potential toward analyst targets.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
